Edding Genor expects H1 net loss of RMB 60 million-RMB 70 million vs year-ago profit

• Edding Genor flagged a first-half swing to loss, citing weaker sales, higher R&D spending, and pricing pressure expectations.
• Revenue forecast at RMB 850 million to RMB 900 million, down from RMB 1.14 billion a year earlier.
• Net result seen at a loss of RMB 60 million to RMB 70 million, versus profit of RMB 114.6 million.
• Vancomycin injection added to China’s 12th centralized procurement in mid-2026, hitting sales ahead of second-half implementation.
• Innovative drugs expected to lift gross sales about 50%, supported by US$ 48.42 million cash proceeds from the GB261 transaction in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12295102), on August 21, 2026, and is solely responsible for the information contained therein.